- Home
- MXCT vs ABVX Comparison
MXCT vs ABVX Comparison
Compare MXCT & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MXCT
- ABVX
- Stock Information
- Founded
- MXCT 1999
- ABVX 2013
- Country
- MXCT United States
- ABVX France
- Employees
- MXCT N/A
- ABVX N/A
- Industry
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ABVX
- Sector
- MXCT Health Care
- ABVX
- Exchange
- MXCT Nasdaq
- ABVX Nasdaq
- Market Cap
- MXCT 361.8M
- ABVX 407.6M
- IPO Year
- MXCT 2021
- ABVX N/A
- Fundamental
- Price
- MXCT $2.71
- ABVX $5.89
- Analyst Decision
- MXCT Strong Buy
- ABVX Buy
- Analyst Count
- MXCT 2
- ABVX 8
- Target Price
- MXCT $10.00
- ABVX $34.63
- AVG Volume (30 Days)
- MXCT 701.5K
- ABVX 328.4K
- Earning Date
- MXCT 03-11-2025
- ABVX 03-24-2025
- Dividend Yield
- MXCT N/A
- ABVX N/A
- EPS Growth
- MXCT N/A
- ABVX N/A
- EPS
- MXCT N/A
- ABVX N/A
- Revenue
- MXCT $38,627,000.00
- ABVX $11,172,999.00
- Revenue This Year
- MXCT $20.01
- ABVX $371.31
- Revenue Next Year
- MXCT $26.64
- ABVX N/A
- P/E Ratio
- MXCT N/A
- ABVX N/A
- Revenue Growth
- MXCT N/A
- ABVX 135.94
- 52 Week Low
- MXCT $2.62
- ABVX $5.50
- 52 Week High
- MXCT $5.26
- ABVX $16.63
- Technical
- Relative Strength Index (RSI)
- MXCT 27.30
- ABVX 36.23
- Support Level
- MXCT $2.62
- ABVX $5.60
- Resistance Level
- MXCT $3.17
- ABVX $7.85
- Average True Range (ATR)
- MXCT 0.17
- ABVX 0.61
- MACD
- MXCT -0.02
- ABVX -0.09
- Stochastic Oscillator
- MXCT 11.27
- ABVX 12.89
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.